Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tirabrutinib - Gilead Sciences/Ono Pharmaceutical

Next Previous
Drug Profile

Tirabrutinib - Gilead Sciences/Ono Pharmaceutical

Alternative Names: GS-4059; ONO-4059; Tirabutinib hydrochloride - Gilead Sciences/Ono Pharmaceutical; Velexbru

Latest Information Update: 08 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Gilead Sciences; Ono Pharmaceutical
  • Class Alkynes; Amines; Antineoplastics; Antirheumatics; Ketones; Phenyl ethers; Purines; Pyrrolidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia; Lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lymphoma
  • Registered Waldenstrom's macroglobulinaemia
  • Phase III Pemphigus
  • Phase II B-cell lymphoma; Chronic lymphocytic leukaemia
  • No development reported Scleroderma
  • Discontinued Chronic urticaria; Rheumatoid arthritis; Sjogren's syndrome

Most Recent Events

  • 05 Aug 2025 Ono Pharmaceutical plans a phase-III trial for Non-Hodgkin's-lymphoma (Second-line therapy or greater) in November 2025 (PO), (NCT07104032)
  • 28 May 2025 Efficacy and adverse event data from the phase II PROSPECT trial in Lymphoma released by Ono Pharmaceuticals
  • 25 Sep 2024 Gilead Sciences terminates a phase I trial in B-cell lymphoma (Combination therapy, Second-line therapy or greater) in the US, France and United Kingdom (PO) (NCT02457598) due to no efficacy advantage (NCT02457598)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top